Clinical Trials for Rectal Cancer
489 rectal cancer trials indexed, 256 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Rectal Cancer
Rectal cancer is a type of cancer that begins in the rectum, which is the last several inches of the large intestine before the anus. It develops when cells in the rectal lining grow uncontrollably, forming tumors. These tumors can invade nearby tissues or spread to other parts of the body. Doctors diagnose rectal cancer through a combination of methods, including physical exams, colonoscopy, biopsy, and imaging tests like CT scans or MRIs. A biopsy, where a small tissue sample is taken from the tumor, confirms the presence of cancer cells.
Common symptoms of rectal cancer include changes in bowel habits, such as diarrhea or constipation, blood in the stool, and a feeling of incomplete bowel emptying. Other signs may include abdominal pain, unexplained weight loss, and fatigue. This type of cancer typically affects adults over the age of 50, but younger people can also develop it. Risk factors include a family history of colorectal cancer, certain inherited genetic conditions, a diet high in red or processed meats, smoking, and a sedentary lifestyle.
Rectal cancer is a significant medical and social concern. It accounts for about one-third of colorectal cancer cases, with an estimated 44,850 new rectal cancer cases diagnosed in the United States in 2023. Despite advances in treatment, it remains a leading cause of cancer-related deaths. The economic impact is also considerable, with costs related to treatment, hospital stays, and lost productivity. Early diagnosis and effective treatment are crucial to improving survival rates and quality of life for patients.
The Rectal Cancer Treatment Landscape
The first-line treatment for rectal cancer often involves a combination of surgery, radiation therapy, and chemotherapy. Surgery aims to remove the tumor and some surrounding tissue, which may include part or all of the rectum. Radiation therapy is commonly used before surgery to shrink the tumor and reduce the risk of recurrence. Chemotherapy can be given before or after surgery to target any remaining cancer cells. Treatment plans are tailored based on the cancer stage, tumor location, and the patient’s overall health.
For patients whose cancer returns or does not respond to initial treatment, second- and third-line options are available. These may include targeted therapies and immunotherapy, depending on the tumor’s genetic profile. Chemotherapy drugs such as fluorouracil, oxaliplatin, and irinotecan are often used in these later stages. Targeted drugs may focus on specific molecules involved in cancer growth, while immunotherapy helps the immune system recognize and attack cancer cells. These options provide additional hope but are not effective for everyone.
Despite available treatments, challenges remain. Some patients experience resistance to chemotherapy or targeted drugs, limiting their effectiveness. Side effects such as fatigue, nausea, and neuropathy can affect quality of life and treatment adherence. Moreover, certain subgroups, like those with advanced or metastatic rectal cancer, have poorer outcomes. Research is focused on understanding these treatment gaps, developing new drugs, and finding ways to personalize therapy to improve results and reduce side effects.
Why Clinical Trials Matter for Rectal Cancer
Clinical trials offer patients access to new treatments that are not yet widely available. Participating in a trial often means receiving closer medical monitoring and contributing to research that may help future patients. According to ClinicalTrials.gov, there are currently 489 rectal cancer clinical trials indexed, with 256 actively recruiting participants. These studies explore various treatment approaches, including new drugs, combinations of therapies, and novel delivery methods.
While clinical trials can provide benefits, they also carry risks. The effectiveness of new treatments is not guaranteed, and some participants may receive a placebo or standard treatment instead of the experimental option. Additional clinic visits and tests may be required, which can be time-consuming and inconvenient. Side effects from investigational treatments may also occur, and patients should discuss these potential risks with their healthcare team before enrolling.
The clinical trial landscape for rectal cancer includes studies sponsored by academic institutions, pharmaceutical companies, and cooperative groups. These sponsors work together to design and conduct trials that meet regulatory standards. ClinicalTrials.gov serves as a central registry where patients, caregivers, and healthcare providers can find detailed information about ongoing and completed studies. This transparency helps people make informed decisions about participating in research.
What to Look for in a Rectal Cancer Clinical Trial
Clinical trials for rectal cancer are divided into phases 1 through 4. Phase 1 trials focus on testing the safety of a new treatment and finding the right dose. Phase 2 trials evaluate how well the treatment works and further assess safety. Phase 3 trials compare the new treatment to the current standard treatments to see which is better. Phase 4 trials happen after a treatment is approved to monitor long-term effects. For rectal cancer trials, the most common phase is Phase 1, with 136 trials. There are 127 Phase 2 trials, 27 Phase 3 trials, and 111 trials where the phase is not specified.
When looking at inclusion criteria for rectal cancer trials, several factors are considered. Age is often limited to adults, typically 18 years or older, but some trials may have an upper age limit. Prior treatments are important; some trials require patients who have not had chemotherapy or radiation, while others focus on those who have already received certain therapies. Biomarkers, such as genetic mutations or protein levels, may be required to match patients to targeted treatments. Staging of the cancer is another key factor, with many trials focusing on specific stages like locally advanced or metastatic rectal cancer. The duration of the disease or time since diagnosis can also affect eligibility.
Exclusion criteria help protect patient safety and ensure clear results. Common exclusions include having other serious health conditions like heart disease or uncontrolled infections. Drug interactions are considered to avoid harmful effects when combining trial treatments with other medications. Safety thresholds, such as limits on liver or kidney function, are used to prevent complications. Patients with a history of allergic reactions to similar drugs may also be excluded. These criteria help researchers reduce risks and gather reliable data.
From a patient perspective, practical considerations are important. Trials may last several months to years, depending on the treatment and follow-up needed. The visit schedule can vary, with some requiring weekly visits and others less frequent check-ins. Travel to the trial site can be a challenge, especially if it is far from home. Patients should ask the research team questions like: How long will the trial last? What tests and procedures will I need? Are there costs not covered by insurance? What support is available for travel or other needs? These questions help patients understand the commitment and plan accordingly.
Primary Sources and Further Reading
For patients and caregivers seeking more information about rectal cancer and clinical trials, trusted sources provide detailed and accurate content. These resources can help explain treatment options, trial participation, and ongoing research. They also offer guidance on managing symptoms and understanding the disease.
- National Cancer Institute: Rectal Cancer Treatment
- MedlinePlus: Rectal Cancer
- ClinicalTrials.gov: Rectal Cancer Trials
- Centers for Disease Control and Prevention: Colorectal Cancer
Latest Research and Emerging Treatments for Rectal Cancer (2026)
Research into rectal cancer treatment in 2026 includes several Phase 3 trials testing new drugs and combinations. One study is exploring the use of sotorasib combined with panitumumab and FOLFIRI chemotherapy in patients with metastatic colorectal cancer who have a KRAS p.G12C mutation (NCT06252649). Sotorasib targets this specific genetic mutation to potentially slow cancer growth, while panitumumab is an antibody that blocks a protein involved in tumor development. This approach aims to improve progression-free survival compared to standard chemotherapy alone.
Another trial is testing calderasib with cetuximab and chemotherapy for patients with advanced colorectal cancer carrying the same KRAS mutation (NCT06997497). Calderasib, like sotorasib, is designed to target the KRAS G12C mutation, which is common in some rectal cancers. Cetuximab works by blocking the epidermal growth factor receptor (EGFR), a protein that helps cancer cells grow. Combining these targeted therapies with chemotherapy may offer more effective control of cancer growth.
In addition, a large multi-country study is investigating whether low dose aspirin can improve survival in colorectal cancer patients with certain genetic markers (NCT02647099). Aspirin is known for its anti-inflammatory effects and may help reduce cancer recurrence by affecting blood clotting and inflammation processes. For patients, these new drugs for rectal cancer and treatment strategies could mean more personalized options based on their tumor’s genetic profile. This ongoing rectal cancer research may lead to treatments that better manage the disease and improve quality of life for patients.
Frequently asked questions about Rectal Cancer trials
How do I find Rectal Cancer clinical trials?
The authoritative source for Rectal Cancer clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 489 rectal cancer studies are currently indexed. You can search by entering "rectal cancer" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new rectal cancer trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Rectal Cancer trials in?
Across the 489 rectal cancer trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Rectal Cancer clinical trials are currently recruiting?
As of the latest scan, 256 rectal cancer trials have a "Recruiting" status on ClinicalTrials.gov, out of 489 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting rectal cancer trial matches their tracked condition.
Stay informed about rectal cancer research
Get a weekly briefing with the trials that matter most.